Basic Information

Email Address

• Email Address

  tanaka.kosuke.7rkyoto-u.ac.jp

Professional Memberships

• 日本臨床腫瘍学会
• 米国癌学会（AACR）
• 日本肺癌学会
• 日本呼吸器学会
• 日本癌学会

Academic Degree

• 27 Mar. 2017

  名古屋大学博士（医学）

Academic Resume (Undergraduate School/Majors)

• 京都大学, 医学部医学科, 卒業

Research History

• From 2026, To Present

  Kyoto University, Hakubi Center, 特定准教授
• From 2022, To 2026

  国立がん研究センター 研究所, 腫瘍免疫研究分野, 主任研究員
• From 2020, To 2022

  国立がん研究センター 先端医療開発センター, ゲノムTR分野, 研究員
• From 2017, To 2020

  Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, 博士研究員
• From 2013, To 2017

  愛知県がんセンター中央病院, 呼吸器内科 レジデント
• From 2010, To 2013

  神戸市立医療センター中央市民病院・先端医療センター, 呼吸器内科・総合腫瘍科 専攻医
• From 2008, To 2010

  京都大学医学部附属病院, 初期研修医

Profile

• Profile

   

  
  

   

ID,URL

• J-Global ID

  202301001158327460

• Researcher number

  50894119

researchmap URL

• https://researchmap.jp/kostanak

Research

Research Topics, Overview of the research

• Research Topics

  Tumor Biology, Immunology

Research Interests

• 腫瘍免疫
• ミトコンドリア
• 自然免疫応答
• 分子標的薬
• 薬剤耐性

Research Areas

• Life sciences, Tumor diagnostics and therapeutics
• Life sciences, Immunology
• Life sciences, Tumor biology

Papers

• Apoptosis in Cancer Biology and Therapy.

  Allison Moyer; Kosuke Tanaka; Emily H Cheng

  Annual review of pathology, Jan. 2025, Peer-reviewed, Lead author

  
• WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer.

  Gaku Yamamoto; Kosuke Tanaka; Ryo Kamata; Hitoshi Saito; Tomoko Yamamori-Morita; Takehiro Nakao; Jie Liu; Shunta Mori; Shigehiro Yagishita; Akinobu Hamada; Yuki Shinno; Tatsuya Yoshida; Hidehito Horinouchi; Yuichiro Ohe; Shun-Ichi Watanabe; Yasushi Yatabe; Hidenori Kitai; Satoshi Konno; Susumu S Kobayashi; Akihiro Ohashi

  Cancer letters, 24 Dec. 2024, Peer-reviewed, Lead author, Corresponding author

  
• LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.

  Shunta Mori; Hiroki Izumi; Mitsugu Araki; Jie Liu; Yu Tanaka; Yosuke Kagawa; Yukari Sagae; Biao Ma; Yuta Isaka; Yoko Sasakura; Shogo Kumagai; Yuta Sakae; Kosuke Tanaka; Yuji Shibata; Hibiki Udagawa; Shingo Matsumoto; Kiyotaka Yoh; Yasushi Okuno; Koichi Goto; Susumu S Kobayashi

  Communications biology, 04 Apr. 2024, Peer-reviewed

  
• CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockade.

  Tomoko Yamamori Morita; Jie Yu; Yukie Kashima; Ryo Kamata; Gaku Yamamoto; Tatsunori Minamide; Chiaki Mashima; Miyuki Yoshiya; Yuta Sakae; Toyohiro Yamauchi; Yumi Hakozaki; Shun-Ichiro Kageyama; Akito Nakamura; Eric Lightcap; Kosuke Tanaka; Huifeng Niu; Karuppiah Kannan; Akihiro Ohashi

  Nature communications, 18 Nov. 2023, Peer-reviewed

  
• Transposable elements potentiate radiotherapy-induced cellular immune reactions via RIG-I-mediated virus-sensing pathways.

  Junyan Du; Shun-Ichiro Kageyama; Riu Yamashita; Kosuke Tanaka; Masayuki Okumura; Atsushi Motegi; Hidehiro Hojo; Masaki Nakamura; Hidenari Hirata; Hironori Sunakawa; Daisuke Kotani; Tomonori Yano; Takashi Kojima; Yamato Hamaya; Motohiro Kojima; Yuka Nakamura; Ayako Suzuki; Yutaka Suzuki; Katsuya Tsuchihara; Tetsuo Akimoto

  Communications biology, 05 Aug. 2023, Peer-reviewed

  
• Impacts of the STING-IFNAR1-STAT1-IRF1 pathway on the cellular immune reaction induced by fractionated irradiation.

  Junyan Du; Shun-Ichiro Kageyama; Riu Yamashita; Hidenari Hirata; Yumi Hakozaki; Masayuki Okumura; Atsushi Motegi; Hidehiro Hojo; Masaki Nakamura; Yasuhiro Hirano; Hironori Sunakawa; Tatsunori Minamide; Daisuke Kotani; Kosuke Tanaka; Tomonori Yano; Takashi Kojima; Akihiro Ohashi; Katsuya Tsuchihara; Tetsuo Akimoto

  Cancer science, Apr. 2022, Peer-reviewed

  
• The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.

  Hiroki Izumi; Shingo Matsumoto; Jie Liu; Kosuke Tanaka; Shunta Mori; Kumiko Hayashi; Shogo Kumagai; Yuji Shibata; Takuma Hayashida; Kana Watanabe; Tatsuro Fukuhara; Takaya Ikeda; Kiyotaka Yoh; Terufumi Kato; Kazumi Nishino; Atsushi Nakamura; Ichiro Nakachi; Shoichi Kuyama; Naoki Furuya; Jun Sakakibara-Konishi; Isamu Okamoto; Kageaki Taima; Noriyuki Ebi; Haruko Daga; Akira Yamasaki; Masahiro Kodani; Hibiki Udagawa; Keisuke Kirita; Yoshitaka Zenke; Kaname Nosaki; Eri Sugiyama; Tetsuya Sakai; Tokiko Nakai; Genichiro Ishii; Seiji Niho; Atsushi Ohtsu; Susumu S Kobayashi; Koichi Goto

  Nature, Dec. 2021, Peer-reviewed

  
• Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer.

  Yukie Kashima; Daisuke Shibahara; Ayako Suzuki; Kyoko Muto; Ikei S Kobayashi; David Plotnick; Hibiki Udagawa; Hiroki Izumi; Yuji Shibata; Kosuke Tanaka; Masanori Fujii; Akihiro Ohashi; Masahide Seki; Koichi Goto; Katsuya Tsuchihara; Yutaka Suzuki; Susumu S Kobayashi

  Cancer research, 15 Sep. 2021, Peer-reviewed

  
• Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis.

  Kosuke Tanaka; Helena A Yu; Shaoyuan Yang; Song Han; S Duygu Selcuklu; Kwanghee Kim; Shriram Ramani; Yogesh Tengarai Ganesan; Allison Moyer; Sonali Sinha; Yuchen Xie; Kota Ishizawa; Hatice U Osmanbeyoglu; Yang Lyu; Nitin Roper; Udayan Guha; Charles M Rudin; Mark G Kris; James J Hsieh; Emily H Cheng

  Cancer cell, 13 Sep. 2021, Peer-reviewed, Lead author

  
• Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.

  Kosuke Tanaka; Toyoaki Hida; Yuko Oya; Tatsuya Yoshida; Junichi Shimizu; Tetsuya Mizuno; Hiroaki Kuroda; Noriaki Sakakura; Kenichi Yoshimura; Yoshitsugu Horio; Yukinori Sakao; Yasushi Yatabe

  Cancer, 15 May 2017, Peer-reviewed, Lead author, Corresponding author

  
• Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).

  Akito Hata; Nobuyuki Katakami; Yoshihiro Hattori; Kosuke Tanaka; Shiro Fujita; Yoshikazu Kotani; Takashi Nishimura; Fumio Imamura; Soichiro Yokota; Miyako Satouchi; Kazuya Monden; Kojiro Otsuka; Akihiro Nishiyama; Kazuya Tsubouchi; Toshihiko Kaneda; Hiroshige Yoshioka; Satoshi Morita; Shunichi Negoro

  Cancer chemotherapy and pharmacology, Apr. 2017, Peer-reviewed

  
• Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.

  Kosuke Tanaka; Hirotaka Osada; Yuko Murakami-Tonami; Yoshitsugu Horio; Toyoaki Hida; Yoshitaka Sekido

  Cancer letters, 28 Jan. 2017, Peer-reviewed, Lead author

  
• Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.

  Tatsuya Yoshida; Yuko Oya; Kosuke Tanaka; Junichi Shimizu; Yoshitsugu Horio; Hiroaki Kuroda; Yukinori Sakao; Toyoaki Hida; Yasushi Yatabe

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 Oct. 2016, Peer-reviewed

  
• Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer.

  Tatsuya Yoshida; Yuko Oya; Kosuke Tanaka; Junichi Shimizu; Yoshitsugu Horio; Hiroaki Kuroda; Yukinori Sakao; Toyoaki Hida; Yasushi Yatabe

  Lung cancer (Amsterdam, Netherlands), Jul. 2016, Peer-reviewed

  
• EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma.

  Kosuke Tanaka; Toyoaki Hida; Yuko Oya; Tomoyo Oguri; Tatsuya Yoshida; Junichi Shimizu; Yoshitsugu Horio; Akito Hata; Reiko Kaji; Shiro Fujita; Yoshitaka Sekido; Takeshi Kodaira; Masaki Kokubo; Nobuyuki Katakami; Yasushi Yatabe

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Dec. 2015, Peer-reviewed, Lead author, Corresponding author

  
• A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002).

  Akito Hata; Nobuyuki Katakami; Shiro Fujita; Shigeki Nanjo; Jumpei Takeshita; Kosuke Tanaka; Toshihiko Kaneda; Akihiro Nishiyama; Takashi Nishimura; Atsushi Nakagawa; Kojiro Otsuka; Satoshi Morita; Yoshiko Urata; Shunichi Negoro

  Cancer chemotherapy and pharmacology, Jun. 2015, Peer-reviewed

  
• Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and leptomeningeal metastases.

  Akito Hata; Nobuyuki Katakami; Hiroshige Yoshioka; Jumpei Takeshita; Kosuke Tanaka; Katsuhiro Masago; Shiro Fujita; Reiko Kaji; Yukihiro Imai; Kazuya Monden; Takeshi Matsumoto; Kazuma Nagata; Kyoko Otsuka; Ryo Tachikawa; Keisuke Tomii; Kei Kunimasa; Masahiro Iwasaku; Akihiro Nishiyama; Tadashi Ishida; Yoshihiro Nishimura

  Anticancer research, Feb. 2015, Peer-reviewed

  
• Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.

  Toshihiko Kaneda; Akito Hata; Hiromi Tomioka; Kosuke Tanaka; Reiko Kaji; Shiro Fujita; Keisuke Tomii; Nobuyuki Katakami

  Lung cancer (Amsterdam, Netherlands), Nov. 2014, Peer-reviewed

  
• [Comparison of garenoxacin and levofloxacin for the prophylaxis of febrile neutropenia].

  Akito Hata; Nobuyuki Katakami; Yoshio Masuda; Kenji Takashima; Jumpei Takeshita; Kosuke Tanaka; Reiko Kaji; Shiro Fujita; Takayuki Ose; Naoto Kitajima

  Gan to kagaku ryoho. Cancer & chemotherapy, Sep. 2014, Peer-reviewed

  
• Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapy.

  Jangchul Park; Hidekazu Yamaura; Yasushi Yatabe; Waki Hosoda; Chiaki Kondo; Junichi Shimizu; Yoshitsugu Horio; Kimihide Yoshida; Kosuke Tanaka; Tomoyo Oguri; Yoshihisa Kobayashi; Toyoaki Hida

  Cancer medicine, Feb. 2014, Peer-reviewed

  
• Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer.

  Akito Hata; Nobuyuki Katakami; Kosuke Tanaka; Jumpei Takeshita; Takeshi Matsumoto; Kazuya Monden; Kazuma Nagata; Katsuhiro Masago; Reiko Kaji; Shiro Fujita; Ryo Tachikawa; Kyoko Otsuka; Kojiro Otsuka; Keisuke Tomii

  Anticancer research, Jan. 2014, Peer-reviewed

  
• Prognostic value of bronchoalveolar lavage in patients with non-HIV pneumocystis pneumonia.

  Koji Tamai; Ryo Tachikawa; Keisuke Tomii; Kazuma Nagata; Kojiro Otsuka; Atsushi Nakagawa; Kyoko Otsuka; Takeshi Matsumoto; Kazuya Monden; Jumpei Takeshita; Kosuke Tanaka; Takahisa Kawamura; Takehiro Otoshi; Daichi Fujimoto

  Internal medicine (Tokyo, Japan), 2014, Peer-reviewed

  
• Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.

  Akito Hata; Nobuyuki Katakami; Hiroshige Yoshioka; Jumpei Takeshita; Kosuke Tanaka; Shigeki Nanjo; Shiro Fujita; Reiko Kaji; Yukihiro Imai; Kazuya Monden; Takeshi Matsumoto; Kazuma Nagata; Kyoko Otsuka; Ryo Tachikawa; Keisuke Tomii; Kei Kunimasa; Masahiro Iwasaku; Akihiro Nishiyama; Tadashi Ishida; Yoshihiro Nishimura

  Cancer, 15 Dec. 2013, Peer-reviewed

  
• Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.

  Kosuke Tanaka; Akito Hata; Reiko Kaji; Shiro Fujita; Takehiro Otoshi; Daichi Fujimoto; Takahisa Kawamura; Koji Tamai; Jumpei Takeshita; Takeshi Matsumoto; Kazuya Monden; Kazuma Nagata; Kyoko Otsuka; Atsushi Nakagawa; Ryo Tachikawa; Kojiro Otsuka; Keisuke Tomii; Nobuyuki Katakami

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Jul. 2013, Peer-reviewed, Lead author

  
• Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma.

  Daichi Fujimoto; Keisuke Tomii; Takehiro Otoshi; Takahisa Kawamura; Koji Tamai; Junpei Takeshita; Kosuke Tanaka; Takeshi Matsumoto; Kazuya Monden; Kazuma Nagata; Kyoko Otsuka; Atsushi Nakagawa; Akito Hata; Ryo Tachikawa; Kojiro Otsuka; Hiroshi Hamakawa; Nobuyuki Katakami; Yutaka Takahashi; Yukihiro Imai

  Lung cancer (Amsterdam, Netherlands), May 2013, Peer-reviewed

  
• Serum procalcitonin is a valuable diagnostic marker in acute exacerbation of interstitial pneumonia.

  Kazuma Nagata; Keisuke Tomii; Kojiro Otsuka; Ryo Tachikawa; Atsushi Nakagawa; Kyoko Otsuka; Junpei Takeshita; Kosuke Tanaka; Takeshi Matsumoto; Kazuya Monden; Takahisa Kawamura; Koji Tamai

  Respirology (Carlton, Vic.), Apr. 2013, Peer-reviewed

  
• A case of isolated IgG4-related interstitial pneumonia: a new consideration for the cause of idiopathic nonspecific interstitial pneumonia.

  Kosuke Tanaka; Kazuma Nagata; Keisuke Tomii; Yukihiro Imai

  Chest, Jul. 2012, Peer-reviewed, Lead author, Corresponding author

  
• Evaluation of the chronic obstructive pulmonary disease assessment test for measurement of health-related quality of life in patients with interstitial lung disease.

  Kazuma Nagata; Keisuke Tomii; Kojiro Otsuka; Ryo Tachikawa; Kyoko Otsuka; Junpei Takeshita; Kosuke Tanaka; Takeshi Matsumoto; Kazuya Monden

  Respirology (Carlton, Vic.), Apr. 2012, Peer-reviewed

  
• Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation.

  Kosuke Tanaka; Akito Hata; Yoko Kida; Reiko Kaji; Shiro Fujita; Nobuyuki Katakami; Yukihiro Imai

  Internal medicine (Tokyo, Japan), 2012, Peer-reviewed, Lead author

  

Misc.

• EUS-Guided Sampling of Mediastinal Lymph Nodes and Abdominal Lesions in Lung Cancer

  Toyoaki Hida; Yuko Oya; Kosuke Tanaka; Hiromi Furuta; Naohiro Watanabe; Tatsuya Yoshida; Junichi Shimizu; Yoshitsugu Horio; Kazuo Hara; Yasushi Yatabe

  JOURNAL OF THORACIC ONCOLOGY, Jan. 2017

  
• Clinical Outcomes of Patients with LS-SCLC Treated with Chemoradiotherapy. Can We Find Candidates for Salvage Surgery?

  Junichi Shimizu; Yuko Oya; Kosuke Tanaka; Chiaki Kondo; Hiromi Furuta; Tatsuya Yoshida; Yoshitsugu Horio; Yukinori Sakao; Yasushi Yatabe; Toyoaki Hida

  JOURNAL OF THORACIC ONCOLOGY, Jan. 2017

  
• Association between EGFR T790M status and progression patterns during initial EGFR-TKIs treatment in patients harboring EGFR mutation

  Y. Oya; T. Yoshida; K. Tanaka; H. Kuroda; J. Shimizu; Y. Horio; Y. Sakao; Y. Inaba; T. Hida; Y. Yatabe

  ANNALS OF ONCOLOGY, Dec. 2016

  
• Hippo伝達経路不活化悪性中皮腫細胞においてスタチンがYAP-CD44カスケード抑制を介して増殖を阻害する

  田中 広祐; 長田 啓隆; 村上 優子; 堀尾 芳嗣; 樋田 豊明; 関戸 好孝

  肺癌, Nov. 2016

  
• 既治療非小細胞肺癌におけるNivolumabの使用成績と効果予測因子についての検討

  大矢 由子; 吉田 達哉; 田中 広祐; 古田 裕美; 近藤 千晶; 渡辺 尚宏; 清水 淳市; 堀尾 芳嗣; 樋田 豊明; 坂尾 幸則; 谷田部 恭

  肺癌, Nov. 2016

  
• 高齢者(75歳以上)におけるOsimertinibの安全性の検討

  古田 裕美; 吉田 達哉; 大矢 由子; 田中 広祐; 近藤 千晶; 渡辺 尚之; 清水 淳市; 堀尾 芳嗣; 樋田 豊明; 坂尾 幸則; 谷田部 恭

  肺癌, Nov. 2016

  
• 悪性中皮腫においてHippo伝達経路の共役転写因子YAPがCD44の発現を制御し、これらはスタチンによって阻害される

  田中 広祐; 長田 啓隆; 村上 優子; 並; 堀尾 芳嗣; 樋田 豊明; 関戸 好孝

  日本癌学会総会記事, Oct. 2016

  
• Afatinib獲得耐性後、複数回の再生検にてT790M変異を検出した肺腺癌の1例

  古田 裕美; 吉田 達哉; 大矢 由子; 田中 広祐; 近藤 千晶; 渡辺 尚宏; 清水 淳市; 堀尾 芳嗣; 樋田 豊明; 谷田部 恭

  肺癌, Oct. 2016

  
• Statin inhibits malignant mesothelioma cell growth by inactivating YAP1

  Kosuke Tanaka; Taketo Kato; Akihiro Matsushita; Hiromi Furuta; Yuko Murakami; Hirotaka Osada; Yoshitaka Sekido

  CANCER RESEARCH, Jul. 2016

  
• Effect of duration from initial diagnosis on the frequency of T790M secondary mutation after EGFR-TKI failure in EGFR-mutant lung adenocarcinomas.

  Kosuke Tanaka; Yuko Oya; Tatsuya Yoshida; Junichi Shimizu; Yoshitsugu Horio; Toyoaki Hida; Yukinori Sakao; Yasushi Yatabe

  JOURNAL OF CLINICAL ONCOLOGY, May 2016

  
• Driver oncogene status in early-emerging lung adenocarcinoma

  K. Tanaka; Y. Oya; T. Yoshida; J. Shimizu; Y. Horio; T. Hida; Y. Yatabe

  ANNALS OF ONCOLOGY, Dec. 2015

  
• Differential crizotinib response duration among ALK fusion variants in ALK-positive NSCLC

  T. Yoshida; Y. Oya; K. Tanaka; J. Shimizu; Y. Horio; T. Hida; Y. Yatabe

  ANNALS OF ONCOLOGY, Dec. 2015

  
• ペメトレキセド併用療法を行った進行非扁平上皮非小細胞肺がん患者における生存期間に関与する因子の検討

  清水 淳市; 大矢 由子; 田中 広祐; 吉田 達哉; 堀尾 芳嗣; 谷田部 恭; 樋田 豊明

  肺癌, Oct. 2015

  
• EGFR-TKI獲得耐性後におけるT790M耐性遺伝子変異とFDG/PET-CT所見の関連性の検討

  吉田 達哉; 田中 宏卓; 大矢 由子; 田中 広祐; 清水 淳市; 堀尾 芳嗣; 黒田 浩章; 坂尾 幸則; 樋田 豊明; 谷田部 恭

  肺癌, Oct. 2015

  
• EGFR minor mutationを有する進行・再発NSCLCにおけるcytotoxic chemotherapyとEGFR-TKIsの治療成績

  大矢 由子; 吉田 達哉; 田中 広祐; 清水 淳市; 堀尾 芳嗣; 坂尾 幸則; 谷田部 恭; 樋田 豊明

  肺癌, Oct. 2015

  
• Impact of total lesion glycolysis at pretreatment FDG PET/CT on response duration of EGFR-TKIs in advanced NSCLC harboring EGFR mutation

  T. Yoshida; Y. Oya; K. Tanaka; J. Shimizu; Y. Horio; T. Hida; Y. Yatabe

  EUROPEAN JOURNAL OF CANCER, Sep. 2015

  
• Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients

  T. Yoshida; Y. Oya; K. Tanaka; S. Junichi; H. Yoshitsugu; T. Hida; Y. Yatabe

  EUROPEAN JOURNAL OF CANCER, Sep. 2015

  
• 肺 肺がんのゲノム解析とその臨床応用 EGFR遺伝子陽性肺癌におけるEGFR-TKIs治療効果とtotal lesion glycolysisの相関

  吉田 達哉; 大矢 由子; 田中 広祐; 清水 淳市; 堀尾 芳嗣; 樋田 豊明; 谷田部 恭

  日本癌治療学会誌, Sep. 2015

  
• Oncogenic Profiling in Lung Adenocarcinoma Emerged in the Youth

  Kosuke Tanaka; Yuko Oya; Tatsuya Yoshida; Junichi Shimizu; Yoshitsugu Horio; Toyoaki Hida; Yasushi Yatabe

  JOURNAL OF THORACIC ONCOLOGY, Sep. 2015

  
• Does Pemetrexed/Platinum Fit All Patients with Non-Squamous Non-Small Cell Lung Cancer? A Retrospective Study of Clinical Factors and Outcomes

  Junichi Shimizu; Yuko Oya; Kosuke Tanaka; Tatsuya Yoshida; Yoshitsugu Horio; Yasushi Yatabe; Toyoaki Hida

  JOURNAL OF THORACIC ONCOLOGY, Sep. 2015

  
• Oncogenic Profiling in Lung Adenocarcinoma Emerged in the Youth

  Kosuke Tanaka; Yuko Oya; Tatsuya Yoshida; Junichi Shimizu; Yoshitsugu Horio; Toyoaki Hida; Yasushi Yatabe

  JOURNAL OF THORACIC ONCOLOGY, Sep. 2015

  
• A case of recurrent thymic atypical carcinoid with pleural and peritoneal dissemination six years after thymectomy

  Kosuke Tanaka; Toyoaki Hida; Yukinori Sakao; Yasushi Yatabe

  Japanese Journal of Lung Cancer, 20 Aug. 2015

  
• 術後6年で胸膜・腹膜播種を来した胸腺非定型カルチノイドの1例

  田中広祐; 樋田豊明; 坂尾幸則; 谷田部恭

  「肺癌」, Aug. 2015, Invited, Lead author

  
• Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients.

  Tatsuya Yoshida; Yuko Oya; Junichi Shimizu; Kosuke Tanaka; Yoshitsugu Horio; Toyoaki Hida; Yasushi Yatabe

  JOURNAL OF CLINICAL ONCOLOGY, May 2015

  
• Association between clinical outcome of first EGFR-TKIs and T790M mutation in NSCLC patients harboring EGFR mutation with acquired resistance to EGFR-TKIs.

  Yuko Oya; Tatsuya Yoshida; Kosuke Tanaka; Junichi Shimizu; Yoshitsugu Horio; Yukinori Sakao; Toyoaki Hida; Yasushi Yatabe

  JOURNAL OF CLINICAL ONCOLOGY, May 2015

  
• A PHASE II STUDY OF PEMETREXED IN PS 2 PATIENTS WITH ADVANCED EGFR WILD-TYPE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

  Akito Hata; Kosuke Tanaka; Shiro Fujita; Nobuyuki Katakami; Toshihiko Kaneda; Akihiro Nishiyama; Takashi Nishimura; Kojiro Otsuka; Yoshiko Urata; Shunichi Negoro

  ANNALS OF ONCOLOGY, Oct. 2014

  
• ALK融合遺伝子陽性肺癌におけるvariant別のcrizotinib治療効果の検討

  吉田 達哉; 大矢 由子; 朴 将哲; 清水 淳市; 田中 広祐; 小栗 知世; 堀尾 芳嗣; 坂尾 幸則; 樋田 豊明; 谷田部 恭

  肺癌, Oct. 2014

  
• EGFR exon 18欠失変異陽性肺腺癌の一例

  小栗 知世; 大矢 由子; 田中 広祐; 吉田 達哉; 朴 将哲; 清水 淳市; 堀尾 芳嗣; 谷田部 恭; 樋田 豊明

  肺癌, Oct. 2014

  
• ALK融合遺伝子を有する非小細胞肺癌におけるクリゾチニブ投与による肝障害についての検討

  島 由子; 吉田 達哉; 田中 広祐; 小栗 知世; 朴 将哲; 清水 淳市; 堀尾 芳嗣; 樋田 豊明; 坂尾 幸則; 谷田部 恭

  肺癌, Oct. 2014

  
• HER2変異陽性肺癌の治療効果についての検討

  小栗 知世; 大矢 由子; 田中 広祐; 吉田 達哉; 朴 将哲; 清水 淳市; 堀尾 芳嗣; 富沢 健二; 坂尾 幸則; 谷田部 恭; 樋田 豊明

  肺癌, Oct. 2014

  
• 組織亜型不明の進行非小細胞肺癌に対するペメトレキセド併用療法の効果

  清水 淳市; 大矢 由子; 田中 広祐; 小栗 知世; 吉田 達哉; 朴 将哲; 堀尾 芳嗣; 樋田 豊明; 谷田部 恭

  肺癌, Oct. 2014

  
• EGFR変異陽性肺癌、KRAS変異陽性肺癌、ALK融合遺伝子陽性肺癌の臨床像と画像所見についての検討

  朴 将哲; 大矢 由子; 田中 広祐; 小栗 知世; 吉田 達哉; 清水 淳市; 堀尾 芳嗣; 山浦 秀和; 谷田部 恭; 樋田 豊明

  肺癌, Oct. 2014

  
• 内視鏡で診断し外科切除を行った単純性肺アスペルギローマの1例

  清水 淳市; 大矢 由子; 田中 広祐; 小栗 知世; 吉田 達哉; 朴 将哲; 堀尾 芳嗣; 樋田 豊明; 坂倉 範昭; 坂尾 幸則; 谷田部 恭

  気管支学, Sep. 2014

  
• 気管神経鞘腫の1例

  小栗 知世; 吉田 公秀; 田中 広祐; 朴 将哲; 清水 淳市; 堀尾 芳嗣; 樋田 豊明; 森 俊輔; 千葉 眞人; 小林 祥久; 水野 鉄也; 黒田 浩章; 坂倉 範昭; 坂尾 幸則; 谷田部 恭

  気管支学, Jan. 2014

  
• DIFFERENTIAL EFFICACY OF EGFR-TKI ACCORDING TO VARIANTS OF EXON 19 DELETIONAL MUTATION IN NON-SMALL CELL LUNG CANCER

  Toshihiko Kaneda; Akito Hata; Kosuke Tanaka; Reiko Kaji; Shiro Fujita; Hiromi Tomioka; Keisuke Tomii; Nobuyuki Katakami

  JOURNAL OF THORACIC ONCOLOGY, Nov. 2013

  
• ALK、EGFR遺伝子変異陽性肺腺癌(手術不能3期)における根治的放射線化学療法の有効性

  田中 広祐; 小栗 知世; 朴 将哲; 清水 淳市; 堀尾 芳嗣; 吉田 公秀; 樋田 豊明; 矢田部 恭; 古平 毅; 片上 信之; 高山 賢二; 小久保 雅樹

  肺癌, Oct. 2013

  
• サルベージ手術を行った小細胞肺がん症例の検討

  清水 淳市; 田中 広祐; 小栗 知世; 朴 将哲; 堀尾 芳嗣; 吉田 公秀; 樋田 豊明; 谷田部 恭; 坂尾 幸則

  肺癌, Oct. 2013

  
• 切除不能ALK融合遺伝子陽性肺癌の臨床像と画像所見についての検討

  朴 将哲; 田中 広祐; 小栗 知世; 清水 淳市; 堀尾 芳嗣; 樋田 豊明; 谷田部 恭; 山浦 秀和

  肺癌, Oct. 2013

  
• EGFR遺伝子変異・RET融合遺伝子を其々有した同時性多発肺腺癌の一例

  小栗 知世; 田中 広祐; 朴 将哲; 清水 淳市; 堀尾 芳嗣; 吉田 公秀; 坂尾 幸則; 谷田部 恭; 樋田 豊明

  肺癌, Oct. 2013

  
• Multiple primary malignancies in Japanese patients with non-small cell lung cancer

  Shiro Fujita; Junpei Takeshita; Kosuke Tanaka; Akito Hata; Katsuhiro Masago; Reiko Kaji; Kenji Takayama; Masaki Kokubo; Nobuyuki Katakami

  EUROPEAN RESPIRATORY JOURNAL, Sep. 2013

  
• Rebiopsy of non-small cell lung cancer patients with acquired resistance to EGFR-TKI: Comparison between T790M mutation-positive and -negative populations

  Akito Hata; Nobuyuki Katakami; Hiroshige Yoshioka; Jumpei Takeshita; Kosuke Tanaka; Shigeki Nanjo; Reiko Kaji; Shiro Fujita; Yukihiro Imai; Kazuya Monden; Takeshi Matsumoto; Kazuma Nagata; Kyoko Otsuka; Ryo Tachikawa; Keisuke Tomii; Kei Kunimasa; Masahiro Iwasaku; Akihiro Nishiyama; Tadashi Ishida

  JOURNAL OF CLINICAL ONCOLOGY, May 2012

  
• Cytokeratin 19 fragment (CYFRA21-1) to predict the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) harboring EGFR mutation

  Kosuke Tanaka; Akito Hata; Reiko Kaji; Shiro Fujita; Jumpei Takeshita; Takeshi Matsumoto; Kazuya Monden; Kazuma Nagata; Kyoko Otsuka; Shigeki Nanjo; Ryo Tachikawa; Kojiro Otsuka; Michio Hayashi; Keisuke Tomii; Nobuyuki Katakami

  JOURNAL OF CLINICAL ONCOLOGY, May 2012

  
• Bevacizumab併用化学療法中に突然の皮質盲で発症したRPLS(Reversible Posterior Leukoencephalopathy Syndrome)の1例

  門田 和也; 松本 健; 田中 広祐; 竹下 純平; 永田 一真; 南條 成輝; 大塚 今日子; 立川 良; 大塚 浩二郎; 林 三千雄; 富井 啓介; 片上 信之

  肺癌, Apr. 2011

  
• 肺小細胞癌を合併した胸膜肉腫の1例

  永田 一真; 竹下 純平; 田中 広祐; 松本 健; 門田 和也; 南條 成輝; 大塚 今日子; 立川 良; 大塚 浩二郎; 林 三千雄; 片上 信之; 富井 啓介; 今井 幸弘

  肺癌, Apr. 2011

  

Presentations

• cGAS-STING signaling as a potential biomarker for IO therapy in lung cancer

  Tanaka K

  世界肺癌学会（WCLC）招待講演, 10 Sep. 2023, Invited

  

Books and Other Publications

• EGFR-TKIの耐性克服

  田中広祐, Contributor

  「がん分子標的治療 Vol.20 No.1」メディカルレビュー社, Dec. 2022

  

Industrial Property Rights

• 特願2025-172236, Enhancing Immunogenic Cell Death by Optimizing Molecularly Targeted Therapy

  Hiroyoshi Nishikawa; Kosuke Tanaka

  

Academic, Social Contribution

Academic Contribution

• 日本癌学会, 一般セッション座長

  Panel moderator

  From Sep. 2023

  
• JMSA NY Life Science Forum,一般セッション座長

  Panel moderator

  JMSA（米国日本人医師会）, From 20 Apr. 2019

  

Social Contribution

• もっと知りたい腫瘍について

  Lecturer

  SHARE（米国乳がん・卵巣がん患者支援団体）日本語プログラム, 第5回勉強会, From 23 Aug. 2019